Trial to Study Treatment of Geographic Atrophy with Emixustat Hydrochloride
May 7, 2014
Submit Comments
Emixustat Hydrochloride is an orally dosed compound produced by Acucela in development for the treatment of geographic atrophy (GA) associated with dry age-related macular degeneration (AMD).
Recently published to clinicaltrials.gov were details of a multi-center, randomized, masked, multiple-dose, crossover study of the pharmacokinetics of emixustat hydrochloride in subjects with GA associated with dry AMD.
Click here for details.
Comments
Jump down to form below to submit your own comments
